​Amgen to pay $71 million to settle claims of off-label drug uses

Biotechnology company Amgen Inc. has agreed to pay $71 million to 48 states and the District of Columbia to settle claims that it improperly promoted its top-selling drugs, Aranesp and Enbrel, for uses not approved by the Food and Drug Administration. California will receive $4.6 million from the settlement, Attorney General Kamala Harris announced Tuesday. Harris and the other attorneys general alleged that Amgen (Nasdaq: AMGN) violated state consumer protection laws by promoting Aranesp for dosing…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: news